今日，市场震荡波动，算力股集体走低，现金流ETF（159399）抗跌属性明显，迎大量资金申购。截至 5月26日，现金流ETF（159399）规模超35亿元位居同类第一，流动性较好。 现金流ETF（159399）是以自由现金流作为选股因子的Smart Beta ETF，紧密跟踪富时中国A股自由现金 流聚焦指数，剔除金融和地产行业，优选自由现金流率最高的50只股票，为投资者筛选出了一批A股市 场中的 "现金牛" 企业，为长期投资收益奠定了坚实基础。 指数历史走势来看，富时中国A股自由现金流聚焦指数在2014~2024年十余年的时间年化收益约20%， 远超沪深300和中证红利指数同期表现，并且从2019年开始连续6年实现正收益。 值得关注的是，现金流ETF（159399）合同约定可月月评估分红。截至2025年5月份，已经宣布分红3 次，有望帮助投资者实现落袋为安，改善投资者投资体验。 广发证券表示，在目前没有新的行业逻辑、市场没有出现大幅波动情况下，红利资产可能在6月逐渐进 入逆风期，但对长线投资者而言，逆风期可能是一个很好的介入时间点，在当下外部环境不确定性较大 的背景下，红利资产仍然是长期配置的底仓选择。 注： ...

现金流ETF（159399）是以自由现金流作为选股因子的Smart Beta ETF，紧密跟踪富时中国A股自由现金 流聚焦指数，剔除金融和地产行业，优选自由现金流率最高的50只股票，为投资者筛选出了一批 A 股 市场中的 "现金牛" 企业，为长期投资收益奠定了坚实基础。 注：指数/基金短期涨跌幅及历史表现仅供分析参考，不预示未来表现。市场观点随市场环境变化而变 动，不构成任何投资建议或承诺。文中提及指数仅供参考，不构成任何投资建议，也不构成对基金业绩 的预测和保证。如需购买相关基金产品，请选择与风险等级相匹配的产品。基金有风险，投资需谨慎。 市场不确定性升级，避险正当其时，关注可月月评估分红的现金流ETF（159399）。 （文章来源：每日经济新闻） 消息面，近期特朗普在社交媒体上威胁从6月1日起对进口自欧盟的商品征收50%关税，远高于此前暂缓 实行的20%"对等关税"，市场不确定性再上升。 当前市场尚有波动，现金流丰沛的红利资产避险能力更强。此外，之前国家政策要求企业加大分红次数 和力度，在低利率背景下，自由现金流充裕的企业凭借着分红能力和抗通胀属性，很大概率会成为后续 的吸金主战场。 值得注意的是，现金流 ...

Group 1 - The market experienced fluctuations on May 26, with the ChiNext index leading the decline, particularly in the innovative drug sector, where the Tianhong Innovative Drug ETF (517380) fell by 1.64% after a drop of over 2.6% earlier in the day [1] - The Tianhong Innovative Drug ETF, launched in 2021, tracks the "Hang Seng-Hushen-Hong Kong Innovative Drug Selected 50" index, providing comprehensive coverage of the innovative drug industry across A-shares and Hong Kong stocks [1] - As of May 23, the Tianhong ETF had a scale of 393 million yuan, making it the largest among five AH innovative drug ETFs in the market [1] Group 2 - Xiangcai Securities predicts that by 2025, the domestic innovative drug industry is expected to reach a turning point, shifting from capital-driven growth to profit-driven growth, which may present opportunities for both performance and valuation recovery in the sector [2]

Group 1 - The core viewpoint of the articles highlights the initiation of a profit recovery cycle in the domestic market driven by low inventory levels and a rebound in the second-hand housing market [1][2] - The active pharmaceutical sector is experiencing a vibrant market, with CXO and innovative drug companies leveraging talent and technology barriers to mitigate overseas policy risks [2] - The ETF market in China is witnessing significant growth, with passive equity fund sizes expected to surpass active equity funds for the first time in 2024, indicating a new era of ETF innovation [2][3] Group 2 - The consumption sector is anticipated to enter a recovery window in the second half of the year, with a focus on traditional consumer leaders and emerging consumption trends [1] - Smart Beta ETFs are gaining traction, with the global Smart Beta ETF market projected to reach $2.24 trillion in 2024, reflecting a 21.4% year-on-year growth [3] - The fixed income market is expected to face challenges due to low interest rates, but short-duration investments in quality credit assets are seen as opportunities for excess returns [4][5]

导语："投资大家谈"是点拾投资的公益内容栏目，希望通过每周日不定期的推送，让更多人看到 基金经理对投资和市场的思考。"投资大家谈"栏目内容以公益类的分享为主，不带有基金产品的 代码和信息，也必须来自基金经理的内容创作。 以下文章来源于市值女魔头V老板 ，作者市值女魔头 市值女魔头V老板 . V总港股全球策略，左手pbroe，右手AI科技。驾驭从传统到新锐，古典底蕴到时代肩膀上做投资。资 本界脑洞创意，被称为市值女魔头，罕见的跨一二级资本市场买方市值洞察。杀伐果断，观点超前，战 斗值满分，关注就知道… 同样是在《证券分析》一书中，他表示，面对市场巨大的诱惑，(投资者)如果对很多问题一知半 解，是一件很危险的事情，A little knowledge is a dangerous thing。费雪先生，则更加直言不 讳。 在《如何选择成长股》一书开篇不久，他就直言，股市具有一种欺骗人的气质。巴菲特先生多年 来一直在尖锐批评华尔街一些不正确的理念，就是对格雷厄姆和费雪两位先生所说过的话最好的 印证。 他认为，面临巨大的利益诱惑，华尔街时不时地创造出一些理论话术，误导市场。 在他的各种批评之言论中，其中以对EMH（有 ...

2025 年 5 月 24 日 总量研究 小市值风格占优，私募调研跟踪策略超额明显 ——量化组合跟踪周报 20250524 要点 量化市场跟踪 大类因子表现：本周（2025.05.19-2025.05.23，下同）动量因子和成长性因子 获得正收益（0.12%和 0.04%）；流动性因子、beta 因子和规模因子取得明显 负收益（-0.56%、-0.52%和-0.40%），市场动量效应占优，小市值风格仍较为 显著。 单因子表现：沪深 300 股票池中，本周表现较好的因子有净利润断层(1.30%)、 成交量的 5 日指数移动平均(1.15%)、总资产毛利率 TTM(1.02%)。表现较差的 因子有对数市值因子(-1.02%)、动量弹簧因子(-1.12%)、早盘后收益因子 (-1.29%)。 中证 500 股票池中，本周表现较好的因子有毛利率 TTM(1.65%)、单季度 ROA(1.40%)、单季度总资产毛利率(1.26%)，表现较差的因子有单季度净利润同 比增长率(-0.42%)、5 日反转(-0.49%)、早盘后收益因子(-0.64%)。 流动性 1500 股票池中，本周表现较好的因子有 5 日平均换手率(0 ...

Core Insights - The rapid development of index investment and the diversification of index fund products are highlighted, with a focus on the opportunities and strategies in the ETF era [1][6] - The forum featured discussions on ETF innovations, investment opportunities in the Hong Kong stock market, and the rise of Smart Beta strategies [2][3][4] Group 1: ETF Development and Trends - The scale of passive equity funds in China is projected to reach 4.6 trillion yuan by 2024, surpassing active equity funds for the first time, indicating a new era of ETF innovation [2] - The core of ETF innovation in China lies in optimizing constituent stocks through quantitative strategies, which is expected to be a significant direction for the future [2] - The ETF investment decision system developed by the company utilizes a combination of market analysis, style rotation, and multi-model verification to enhance investment efficiency [2] Group 2: Investment Opportunities in Hong Kong Stocks - The company identifies five core sectors in the Hong Kong stock market: internet, innovative pharmaceuticals, smart vehicles, consumer goods, and dividend assets, which present significant structural opportunities [3] - The acceleration of AI commercialization is reshaping the valuations of leading internet companies, while innovative pharmaceuticals are expanding into new markets [3] - The Hang Seng Index ETF combines dividend and technology attributes, making it an ideal choice for long-term asset allocation [3] Group 3: Smart Beta Strategies - The A-share Smart Beta product scale reached 150.715 billion yuan by Q1 2025, reflecting rapid growth in this investment strategy [4] - Smart Beta strategies are breaking the boundaries between active and passive investments, offering low-cost and stable style advantages [4] - The global Smart Beta ETF market is projected to reach 2.24 trillion USD by 2024, with a year-on-year growth of 21.4%, driven by systematic applications of factor exposure [4] Group 4: Company Initiatives and Future Outlook - The company has developed a comprehensive product matrix covering multiple assets and strategies, catering to diverse investor needs [5] - The introduction of the "E起富" WeChat mini-program aims to provide users with enhanced investment decision-making support [5] - The ETF market is transitioning from simple scale expansion to refined strategy competition, with Smart Beta innovations and the exploration of scarce assets in Hong Kong being key focus areas [6]

Summary of Corbus Pharmaceuticals Holdings (CRBP) 2025 Conference Call Company Overview - **Company**: Corbus Pharmaceuticals Holdings (CRBP) - **Date of Conference**: May 21, 2025 - **Key Speaker**: Yuval Cohen, CEO Key Points Discussed ADC CRB-701 Development - **Data Presentation**: Recent data from the first Western dataset for CRB-701 shows safety and efficacy comparable to existing treatments like PADCEV, particularly in bladder and cervical cancers [5][6] - **Ocular Prophylaxis Impact**: The use of ocular prophylaxis in Western trials resulted in significantly fewer ocular events compared to trials in China [5] - **Head and Neck Cancer**: Initial data from head and neck cancer patients is promising, with a small cohort showing encouraging results [6][8] - **Safety Profile**: CRB-701 demonstrates a markedly safer profile than PADCEV, with fewer adverse events and lower dropout rates [8] - **Market Strategy**: The company aims to target "empty swim lanes" in oncology, focusing on tumor types where PADCEV is not currently used [9][10] Future Data Expectations - **Project OPTIMIZ**: The company is conducting Project OPTIMIZ, which includes trials for bladder, head and neck, and cervical cancers, with significant patient enrollment expected [13][14] - **Data Release Timeline**: More mature data is anticipated to be presented at a major oncology conference later in the year, with a marked increase in patient numbers [14][36] Head and Neck Cancer Focus - **Market Size**: Head and neck cancer represents a significant market opportunity, with approximately 80,000 patients in the US, half of whom may become metastatic [35] - **Regulatory Path**: The regulatory path for head and neck cancer may be more complex compared to cervical cancer, which has a smaller patient population but potentially faster approval timelines [36][37] Combination Therapy Insights - **Checkpoint Inhibitor Combinations**: The company is exploring combinations of CRB-701 with checkpoint inhibitors, with a focus on patient selection based on immune-related biomarkers [23][24] - **Data-Driven Decisions**: Future strategies will be guided by data outcomes, particularly in relation to competing therapies in the market [25][27] Other Drug Developments - **CB1 Inverse Agonist (CRB-913)**: The company is developing CRB-913, which aims to have a safer profile with significantly lower brain penetration compared to competitors, potentially reducing neuropsych adverse events [41][42] - **Phase Ib Studies**: The design of Phase Ib studies will focus on safety and tolerability, with results expected in the second half of the year [49][50] Upcoming Milestones - **Phase One Data**: The company plans to present data for multiple assets in the second half of the year, indicating a busy and potentially impactful period ahead [61] Additional Insights - **Market Competition**: The competitive landscape includes other modalities targeting similar indications, with a focus on differentiating CRB-701 based on its unique safety and efficacy profile [20][21] - **Regulatory Considerations**: The company is aware of the challenges in navigating regulatory pathways, especially for larger indications like head and neck cancer [36][37] This summary encapsulates the key discussions and strategic directions of Corbus Pharmaceuticals as presented in the conference call, highlighting their focus on innovative cancer therapies and the importance of data in guiding their development strategies.

Core Viewpoint - U.S. Global Investors, Inc. has successfully listed its gold-focused ETF, the U.S. Global GO GOLD and Precious Metal Miners ETF (GOAU), on the Bolsa de Valores de Colombia, enhancing its accessibility for Colombian investors and expanding its presence in Latin America [1][2][3] Company Overview - U.S. Global Investors, Inc. is a boutique investment firm specializing in precious metals and emerging markets, with over 50 years of history [7] - The company is headquartered in San Antonio, Texas, and provides money management and other services to various funds and ETFs [7] ETF Details - GOAU offers exposure to companies involved in the production of gold and other precious metals through mining or royalty agreements [2][3] - The ETF is already listed in New York, Mexico, and Peru, and its addition to the BVC increases its visibility across Latin America [2] - GOAU is the only non-UCITS ETF listed on the BVC that provides access to gold and precious metals mining companies [3] Investment Strategy - The GoGold ETF employs a smart-factor, rules-based investment strategy that combines passive investing efficiency with active management selectivity [5] - It tracks the U.S. Global GO GOLD and Precious Metal Miners Index, which screens companies based on valuation, profitability, and balance sheet quality [5][13] - Unlike traditional gold mining funds, GOAU focuses on high-quality, well-managed companies with consistent profitability, particularly North American royalty and streaming companies [6] Market Context - The listing of GOAU on the BVC is seen as timely due to the growing sophistication of Colombia's capital markets and increasing demand for diversified investment options amid economic uncertainty and geopolitical instability [3] - As of May 2025, only two gold-related ETFs are listed on the BVC, highlighting the unique position of GOAU in the Colombian market [3]

Market Overview - Wall Street experienced a strong bull run in 2023 and 2024, but 2025 has shown mixed results due to concerns over persistent inflation and the Federal Reserve's uncertain stance on interest rates after a 1% cut in the benchmark lending rate last year [1] - Severe volatility has affected Wall Street since early April, primarily due to the implementation of reciprocal tariff policies by the Trump administration, with baseline tariffs at 10% but actual rates exceeding 70% for several major trading partners [2] - Retaliatory tariffs from other countries have raised fears of a global trade war, although some trade negotiations have been settled and others are ongoing [3] Company Highlights Philip Morris International Inc. (PM) - Philip Morris has shown strong pricing power and is expanding its smoke-free product portfolio, aiming to become substantially smoke-free by 2030 [7] - The company anticipates robust growth in 2025, with a projected 2% increase in volume and smoke-free products expected to grow by 12-14% [8] - Expected revenue and earnings growth rates for the current year are 8.1% and 13.7%, respectively, with a stock price increase of 44.7% year to date [9] Sprouts Farmers Market Inc. (SFM) - Sprouts Farmers is focusing on product innovation, e-commerce, and private label offerings, which have contributed to better-than-expected fourth-quarter 2024 results [10] - The company expects net sales to rise between 10.5% and 12.5% in 2025, with comparable sales anticipated to increase by 4.5-6.5% [11] - Expected revenue and earnings growth rates for the current year are 13.7% and 35.5%, respectively, with a stock price surge of 32.2% year to date [12] Newmont Corp. (NEM) - Newmont is progressing with growth projects, including the Tanami expansion and the acquisition of Newcrest, which enhances its portfolio and synergies [13] - The Ahafo North project has received full funding approval, with commercial production expected to start in the second half of 2025, involving an investment of $950 million to $1,050 million [14] - Expected revenue and earnings growth rates for the current year are 2% and 12.6%, respectively, with a stock price increase of 40.5% year to date [15]